Company news

Neuropace, Inc. news in 2025

Neuropace, Inc.'s news releases, calls and decks from 2025, newest first.

View company

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 31, 2025

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

December 17, 2025

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

December 8, 2025

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

December 2, 2025

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

November 24, 2025

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

November 4, 2025

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

October 22, 2025

NeuroPace to Participate in Upcoming Healthcare Conferences

August 28, 2025

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

August 12, 2025

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

August 1, 2025

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

July 29, 2025

NeuroPace Announces Strategic CFO Transition

June 24, 2025

NeuroPace Secures Up to $75 Million in Debt Financing

June 4, 2025

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 27, 2025

NeuroPace Reports First Quarter 2025 Financial Results

May 13, 2025

NeuroPace Provides Update on Tariff Status

April 14, 2025

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

April 8, 2025

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

April 3, 2025

NeuroPace Announces Refocusing of Product Portfolio

April 2, 2025

NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference

March 26, 2025

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

March 4, 2025

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

March 3, 2025

NeuroPace to Present at the Leerink Partners Global Healthcare Conference

March 3, 2025

NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.

February 20, 2025

NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

February 19, 2025

NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

February 18, 2025

NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock

February 13, 2025

NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock

February 12, 2025

NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

February 2, 2025

NeuroPace Issues 2025 Financial Guidance Targets

January 27, 2025

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates

January 7, 2025

Calls in 2025

Decks in 2025